{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T14:00:44Z","timestamp":1777039244539,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Everolimus is an inhibitor of mammalian target of rapamycin (mTOR) used in both transplantation and cancer treatment (breast, renal and neuroendocrine). In transplantation, therapeutic drug monitoring (TDM) is recommended due to the potential drug\u2013drug interactions with chronic medications, which can affect everolimus pharmacokinetics. In cancer treatment, everolimus is used at higher doses than in transplantation and without a systematic drug monitoring.<\/jats:p><jats:p>We present a case report of a 72-year-old woman with epilepsy history to whom everolimus 10\u00a0mg QD was prescribed as third line of treatment for renal cell carcinoma (RCC). The potential drug interactions between everolimus and the patient's chronic medications, carbamazepine and phenytoin, are significant as both are known as strong inducers CYP3A4 metabolism, potentially leading to underexposure to everolimus.<\/jats:p><jats:p>TDM of everolimus was recommended by the pharmacist. The literature suggests that a minimum plasma concentration (Cminss) of everolimus over 10\u00a0ng\/ml is associated with better response to treatment and progression-free survival (PFS). The patient\u2019s everolimus dose had to be increased until 10\u00a0mg BID, and regular monitoring of everolimus levels showed an increase in Cminss from 3.7\u00a0ng\/ml to 10.8\u00a0ng\/ml.<\/jats:p><jats:p>This case highlights the importance of checking for potential drug interactions and monitoring everolimus levels in patients on chronic medication, especially those with several inducers or inhibitors of CYP3A4 metabolism. TDM can help to ensure that patients are treated with their optimal dose, which can improve the effectiveness of the treatment or minimize the risk of toxicities.<\/jats:p>","DOI":"10.1186\/s40001-023-01172-w","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T02:01:59Z","timestamp":1688004119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["First reported double drug\u2013drug interaction in a cancer renal patient under everolimus treatment: therapeutic drug monitoring and review of literature"],"prefix":"10.1186","volume":"28","author":[{"given":"Eduard","family":"Fort-Casamartina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carme","family":"Mu\u00f1oz-Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul Francisco","family":"Rigo-Bonnin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela Maria","family":"del Valle-Celiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00faria","family":"Gonzalo-Diego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Otero-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Bleda-Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Prats-Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Fontanals-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"issue":"7","key":"1172_CR1","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.3390\/ijms21072532","volume":"21","author":"Deleuze","year":"2020","unstructured":"Deleuze, et al. Immunotherapy in renal cell carcinoma: the future Is now. Int J Mol Sci. 2020;21(7):2532.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1172_CR2","doi-asserted-by":"publisher","first-page":"e001079","DOI":"10.1136\/esmoopen-2020-001079","volume":"5","author":"L Albiges","year":"2020","unstructured":"Albiges L, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020;5(6):e001079. https:\/\/doi.org\/10.1136\/esmoopen-2020-001079.","journal-title":"ESMO Open"},{"issue":"9","key":"1172_CR3","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"Choueri","year":"2021","unstructured":"Choueri, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829\u201341.","journal-title":"N Engl J Med"},{"issue":"3","key":"1172_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1470-2045(23)00049-9","volume":"24","author":"Choueri","year":"2023","unstructured":"Choueri, et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol. 2023;24(3):228\u201338.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1172_CR5","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","volume":"21","author":"Powles","year":"2020","unstructured":"Powles, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(12):1563\u201373.","journal-title":"Lancet Oncol"},{"key":"1172_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2147\/CE.S98687","volume":"11","author":"Buti","year":"2016","unstructured":"Buti, et al. Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy. Core Evidence. 2016;11:23\u201336.","journal-title":"Core Evidence"},{"issue":"9637","key":"1172_CR7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Gr\u00fcnwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449\u201356.","journal-title":"Lancet"},{"issue":"6","key":"1172_CR8","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EGE, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, \u00d6berg K, RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514\u201323.","journal-title":"N Engl J Med"},{"issue":"10","key":"1172_CR9","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1001\/jamaoncol.2018.2262","volume":"4","author":"G Jerusalem","year":"2018","unstructured":"Jerusalem G, de Boer RH, Hurvitz S, Yardley DA, Kovalenko E, Ejlertsen B, Blau S, \u00d6zg\u00fcroglu M, Landherr L, Ewertz M, Taran T, Fan J, Noel-Baron F, Louveau AL, Burris H. Everolimus Plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncol. 2018;4(10):1367\u201374.","journal-title":"JAMA Oncol"},{"issue":"2","key":"1172_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1399-0012.2005.00326.x","volume":"19","author":"MI Lorber","year":"2005","unstructured":"Lorber MI, Ponticelli C, Whelchel J, Mayer HW, Kovarik J, Li Y, Schmidli H. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Clin Transpl. 2005;19(2):145\u201352.","journal-title":"Clin Transpl"},{"issue":"2","key":"1172_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/FTD.0000000000000260","volume":"38","author":"M Shipkova","year":"2016","unstructured":"Shipkova M, Hesselink DA, Holt DW, Billaud EM, van Gelder T, Kunicki PK, Brunet M, Budde K, Barten MJ, De Simone P, Wieland E, L\u00f3pez OM, Masuda S, Seger C, Picard N, Oellerich M, Langman LJ, Wallemacq P, Morris RG, Thompson C, Marquet P. Therapeutic drug monitoring of everolimus: a consensus report. Ther Drug Monit. 2016;38(2):143\u201369.","journal-title":"Ther Drug Monit"},{"issue":"9","key":"1172_CR12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/bdd.524","volume":"27","author":"JM Kovarik","year":"2006","unstructured":"Kovarik JM, Beyer D, Schmouder RL. Everolimus drug interactions: application of a classification system for clinical decision making. Biopharm Drug Dispos. 2006;27(9):421\u20136.","journal-title":"Biopharm Drug Dispos"},{"issue":"7\u20138","key":"1172_CR13","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1345\/aph.1R769","volume":"47","author":"JA Grabowsky","year":"2013","unstructured":"Grabowsky JA. Drug interactions and the pharmacist: focus on everolimus. Ann Pharmacother. 2013;47(7\u20138):1055\u201363.","journal-title":"Ann Pharmacother"},{"key":"1172_CR14","doi-asserted-by":"publisher","first-page":"670862","DOI":"10.3389\/fphar.2021.670862","volume":"12","author":"L Molenaar-Kuijsten","year":"2021","unstructured":"Molenaar-Kuijsten L, Van Balen DEM, Beijnen JH, Steeghs N, Huitema ADR. A review of CYP3A drug-drug interaction studies: practical guidelines for patients using targeted oral anticancer drugs. Front Pharmacol. 2021;12:670862.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1172_CR15","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/FTD.0000000000000628","volume":"41","author":"S Falkowski","year":"2019","unstructured":"Falkowski S, Woillard J-B. Therapeutic drug monitoring of everolimus in oncology: evidences and perspectives. Ther Drug Monit. 2019;41(5):568\u201374.","journal-title":"Ther Drug Monit"},{"key":"1172_CR16","doi-asserted-by":"crossref","unstructured":"W Cheung\u00a0,\u00a0C Ligia\u00a0,\u00a0A Jappe\u00a0,\u00a0O. Anak. Pharmacokinetic (PK) profile of a single dose of everolimus (10 mg) administered with a low- or high-fat meal and under fasting conditions in healthy subjects. Meeting Abstract | 2011 Annual Meeting I. 2011.","DOI":"10.1200\/jco.2011.29.15_suppl.e15080"},{"issue":"3","key":"1172_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ejca.2013.11.022","volume":"50","author":"A Ravaud","year":"2014","unstructured":"Ravaud A, Urva SR, Grosch K, Cheung WK, Anak O, Sellami DB. Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncology. Eur J Cancer. 2014;50(3):486\u201395.","journal-title":"Eur J Cancer"},{"issue":"9","key":"1172_CR18","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00228-019-02704-2","volume":"75","author":"M Hirabatake","year":"2019","unstructured":"Hirabatake M, Mizuno T, Kato H, Hashida T. Everolimus pharmacokinetics and exposure-response relationship in Japanese patients with advanced breast cancer. Eur J Clin Pharmacol. 2019;75(9):1309\u201318.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1172_CR19","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1365-2125.2005.02434.x","volume":"60","author":"JM Kovarik","year":"2005","unstructured":"Kovarik JM, Beyer D, Bizot MN, Jiang Q, Allison MJ, Schmouder RL. Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. Br J Clin Pharmacol. 2005;60(4):434\u20137.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1172_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00228-004-0866-5","volume":"61","author":"JM Kovarik","year":"2005","unstructured":"Kovarik JM, Beyer D, Bizot MN, Jiang Q, Shenouda M, Schmouder RL. Effect of multiple-dose erythromycin on everolimus pharmacokinetics. Eur J Clin Pharmacol. 2005;61(1):35\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"1172_CR21","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1177\/1078155220904761","volume":"26","author":"G Strobbe","year":"2020","unstructured":"Strobbe G, Pannier D, Sakji I, Villain A, Feutry F, Marliot G. Advantages of everolimus therapeutic drug monitoring in oncology when drug-drug interaction is suspected: a case report. J Oncol Pharm Pract. 2020;26(7):1743\u20139.","journal-title":"J Oncol Pharm Pract"},{"issue":"8","key":"1172_CR22","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1177\/1060028016648342","volume":"50","author":"AR Miesner","year":"2016","unstructured":"Miesner AR, Ausman M, Dagraedt B, Zieminski J. Probable drug interaction between everolimus and clarithromycin. Ann Pharmacother. 2016;50(8):689\u201390.","journal-title":"Ann Pharmacother"},{"issue":"6","key":"1172_CR23","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/jcpt.12572","volume":"42","author":"PN Tran","year":"2017","unstructured":"Tran PN, Pinter-Brown LC. Everolimus-induced nephrotic syndrome precipitated by interaction with voriconazole in a patient with Hodgkin\u2019s lymphoma. J Clin Pharm Ther. 2017;42(6):776\u20139.","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"1172_CR24","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/annonc\/mdu492","volume":"26","author":"O Mir","year":"2015","unstructured":"Mir O, Poinsignon V, Arnedos M, Delaloge S, Paci A. Pharmacokinetic interaction involving fenofibrate and everolimus. Ann Oncol. 2015;26(1):248\u20139.","journal-title":"Ann Oncol"},{"key":"1172_CR25","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s40262-017-0582-9","volume":"57","author":"RB Verheijen","year":"2018","unstructured":"Verheijen RB, Atrafi F, Schellens JHM, Beijnen JH, Huitema ADR, Mathijssen RHJ, Steeghs N. Pharmacokinetic optimization of everolimus dosing in oncology: a randomized crossover trial. Clin Pharmacokinet. 2018;57:637\u201344.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1172_CR26","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","volume":"17","author":"TK Choueiri","year":"2016","unstructured":"Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ, METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917\u201327.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1172_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ejca.2011.11.027","volume":"48","author":"E Calvo","year":"2012","unstructured":"Calvo E, Escudier B, Motzer RJ, et al. Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer. 2012;48(3):333\u20139.","journal-title":"Eur J Cancer"},{"issue":"15","key":"1172_CR28","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","volume":"16","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473\u201382.","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01172-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-023-01172-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01172-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T02:03:12Z","timestamp":1688004192000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-023-01172-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1172"],"URL":"https:\/\/doi.org\/10.1186\/s40001-023-01172-w","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]},"assertion":[{"value":"30 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"When everolimus treatment was started verbal patient consent to participate was obtained after Pharmaceutical Care. It was recorded on electronical medical history. Verbal consent of the patient\u2019s daughter to publish was obtained before submitting paper and was recorded on electronic medical history.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval consent to participate"}},{"value":"No interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"202"}}